Classical Treatment (classical + treatment)

Distribution by Scientific Domains


Selected Abstracts


Continuous intravenous lidocaine in the treatment of paralytic ileus due to severe spinal cord injury

ACTA ANAESTHESIOLOGICA SCANDINAVICA, Issue 1 2009
A. BAUMANN
Paralytic ileus is a major concern in the acute phase of spinal cord injury. Classical treatment with neostigmine is often ineffective. Continuous intravenous (i.v.) lidocaine infusion has been previously proposed intra and post-operatively in order to decrease the duration of post-operative ileus after abdominal surgery. We report the cases of seven patients suffering from complete paralytic spinal cord injury-related ileus with colectasy resistant to neostigmine, who were treated by i.v. lidocaine infusion. [source]


Efficient Allocations in Club Economies

JOURNAL OF PUBLIC ECONOMIC THEORY, Issue 1 2004
Marcus Berliant
We explore the characteristics of Pareto-optimal allocations in the context of local public goods or clubs. A set of first-order conditions for Pareto optimality is provided. Classical treatments apparently neglect an important term related to migrant compensation, and thus are incorrect. A Pareto optimum is shown to exist. [source]


Therapeutic Hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin

DERMATOLOGIC THERAPY, Issue 2 2010
Gulsum Gencoglan
ABSTRACT Psychocutaneous conditions are frequently encountered in dermatology practice. Prurigo nodularis and lichen simplex chronicus are two frustrating conditions that are classified in this category. They are often refractory to classical treatment with topical corticosteroids and antihistamines. Severe, generalized exacerbations require systemic therapy. Phototherapy, erythromycine, retinoids, cyclosporine, azathiopurine, naltrexone, and psychopharmacologic agents (pimozide, selective serotonin reuptake inhibitor antidepressants) were tried with some success. Here five cases with lichen simplex chronicus and four cases with prurigo nodularis, who responded well to gabapentin, are presented. [source]


Treatment of alcoholic hepatitis

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Issue 4 2002
Jacquelyn J Maher
Abstract, Alcoholic hepatitis is a common disease with an overall 1-year mortality of 20%. Although the classical treatment for alcoholic hepatitis is abstinence, in some individuals abstinence alone is inadequate to promote survival and recovery. This is particularly true of patients with severe alcoholic hepatitis, who are identified by jaundice, coagulopathy and neutrophilia. Within the last two decades, several agents have been examined as treatments for alcoholic hepatitis and cirrhosis. They have targeted several key processes in the pathophysiology of alcoholic liver disease, including hypermetabolism, inflammation, cytokine dysregulation and oxidant stress. The compounds that offer the greatest survival benefit to patients with severe alcoholic hepatitis are corticosteroids. Several groups have reported excellent results with corticosteroids, but positive results are not uniform, and there remains some controversy over their efficacy. Even if corticosteroids are beneficial for alcoholic hepatitis, they are not recommended for all patients at risk. Consequently, other agents are being tested that have broader applicability to individuals with contraindications to steroids. In this regard, pentoxifylline shows some promise, as does enteral feeding with medium chain triglycerides. Independent efforts are also being directed toward treatment of chronic alcoholic liver disease and alcoholic cirrhosis. Anti-oxidants have received the greatest attention; drugs such as S -adenosyl-methionine may be of benefit. This and others are under active study. 2002 Blackwell Publishing Asia Pty Ltd [source]


Review article: albumin in the treatment of liver diseases,new features of a classical treatment

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 2002
V Arroyo
Summary Albumin was introduced initially in the treatment of patients with cirrhosis and ascites to increase serum albumin concentration due to its oncotic effect. Although its administration declined some years later, at present it constitutes an essential treatment in clinical hepatology. Several studies have clearly demonstrated its efficacy in the prevention and treatment of circulatory dysfunction and hepatorenal syndrome in patients with cirrhosis. These effects can be due not only to its properties as a plasma expander but also to its capacity to bind numerous substances such as bile acids, nitric oxide and cytokines. Based on this capacity an albumin dialysis system (MARS) has recently been developed. The usefulness of this system in the management of patients with acute and chronic liver failure is, at present, under evaluation. [source]


SPECIALIZATION AND TRADE: A GAME THEORETICAL APPROACH

PACIFIC ECONOMIC REVIEW, Issue 4 2006
Shuntian Yao
Different from the classical treatment, we adopt a game theoretical approach. Therefore in our models the prices of traded goods are endogenously formulated according to the bidding strategies of the producer-consumers. Furthermore, we assume that in the beginning individuals randomly choose their professions. As a result, with a short-run Nash equilibrium different types of professionals may have different utility levels; while through a dynamic process, a long-run Nash equilibrium with utility equalization is reached. Besides, we also attempt to provide a new algorithm for the computation of general equilibrium models in the Yang-Ng framework. [source]


3233: Effectiveness of a new lubricant for dry eye after photoablation using an osmolarity measurement

ACTA OPHTHALMOLOGICA, Issue 2010
B COCHENER
Purpose LASIK has been shown to lead to corneal hypoesthesia, which can trigger a decrease in the reflex arc regulating tears secretion. The goal of this study was to evaluate the benefits of a new lubricant after LASIK compared to a classical treatment by measuring tear osmolarity. Methods Twenty patients scheduled to undergo LASIK were enrolled in the study and randomized into two groups. A baseline osmolarity measurement was taken (TearLab Osmolarity System, TearLab Corp) and then randomized into one of two groups. Patients in the first group received two artificial tears (Refresh and Celluvisc, Allergan) following surgery while the 2nd group received a PEG 400 and hylauronic acid (HA) artificial tear (Blink, Abbott Medical Optics) following treatment. These patients were assessed at 1 month postoperative for changes in osmolarity. Results Normal values of osmolarity with Tear Lab range between 275 and 308 mOsm/L; above this, we consider that the eye is dry. The single tear treatment had the same efficiency as our standard two-drop therapy. No side effects were noted in any patients. Most patients found it easier to have only one kind of lubricant instead of a combination of two, which lead to a better observance. The use of the tear osmolarity system provided a quick, reliable test for detecting patient with a risk of postoperative dry eye and for assessing the effectiveness of the therapy. Conclusion The new lubricant, Blink, is another choice in the therapeutic panel for treatment of dry eye disease. It is well tolerated and as efficient as the combination of Refresh and Celluvisc. New osmolarity measurement is an easy, fast and non-invasive well tolerated test for detecting infraclinical dryness especially before refractive surgery. [source]


New and innovative therapies for Behcet's disease

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, Issue 2 2004
Fereydoun DAVATCHI
Abstract Background:, Behcet's disease (BD) is a vasculitis progressing by attacks and remissions. Not all patients will respond even to the classical treatments. New treatments are emerging with the hope to overcome this failure. Biologic agents:, Interferon-, (IFN-,), anti-tumour necrosis factor-, (TNF-,), and tolerization have been used in BD. IFN-, is mainly used for ocular manifestations of BD. The result seems impressive, 92% of cases had good or excellent results. It was less impressive for mucocutaneous and joint manifestations. The dosage is 6,9 million IU/day for 4 weeks, then 4.5 million daily for 4 weeks, and then 3 million/day. The maintenance dose is 3 millions, three times/week, to continue for 8 weeks after complete remission. Etanercept (anti-TNF-,) was effective in mucocutaneous lesions of BD at the dosage of 25 mg twice weekly for 3 months (double-blind control study). Attacks relapsed after discontinuation. Etanercept was ineffective in ocular lesions (open study). Infliximab (anti-TNF-,) was very effective in many studies of ocular lesions. It dramatically suppressed the inflammatory attack. The dosage is one injection of 5 mg/kg (intravenous infusion) at weeks 0, 2, 6, and then every 8 weeks. Tolerization with oral administration of HSP peptide 336,351 seems to protect from uveitis relapse. Pentoxifylline is not particularly effective unless for oral aphthae (50% response rate). Pimecrolimus ointment may be of help in resistant genital aphthosis, reducing the healing time. [source]